Cargando…
A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic arm...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240065/ https://www.ncbi.nlm.nih.gov/pubmed/28217522 http://dx.doi.org/10.4103/2230-8210.196016 |